Dr. Daniel J. Wallace, MD
Rheumatology (Rheumatology Physician)
414 N Camden Drive, Suite 1100
Beverly Hills, CA 90210
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
Medicare and federal program status
Opted out of Medicare from March 27, 2024 through March 27, 2028. Medicare does not pay for this clinician’s services: patients with Medicare sign a private contract and pay the clinician directly. They can still order tests and refer Medicare patients to other providers.
Source: CMS Medicare Opt Out Affidavits (record last updated April 16, 2026). Opting out is a legal choice many clinicians make, often to run a cash or concierge practice.
At a glance
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 62
Licensed in California since 1975, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
CA license G30533 (first issued 1975; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 62
- Services billed
- 7,050
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 39,200 | 14 |
| Injection, tocilizumab, 1 mg | 38,772 | 16 |
| Injection, inclisiran, 1 mg | 12,632 | 29 |
| Injection, denosumab, 1 mg | 6,540 | 81 |
| Injection, golimumab, 1 mg, for intravenous use | 6,081 | 12 |
| Injection, belimumab, 10 mg | 5,623 | 11 |
| Injection, benralizumab, 1 mg | 1,380 | 12 |
| Injection of drug or substance under skin or into muscle | 768 | 212 |
| Measurement of complement (immune system proteins), antigen, | 589 | 240 |
| Gammaglobulin (immune system protein) measurement | 484 | 151 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydroxychloroquine Sulfate Other prescribers in Beverly Hills, CA | 186 |
| Prednisone Other prescribers in Beverly Hills, CA | 169 |
| Methotrexate (methotrexate sodium) Other prescribers in Beverly Hills, CA | 84 |
| Levothyroxine Sodium Other prescribers in Beverly Hills, CA | 70 |
| Meloxicam Other prescribers in Beverly Hills, CA | 59 |
| Celecoxib Other prescribers in Beverly Hills, CA | 57 |
| Gabapentin Other prescribers in Beverly Hills, CA | 55 |
| Leflunomide Other prescribers in Beverly Hills, CA | 42 |
| Rinvoq (upadacitinib) | 41 |
| Folic Acid Other prescribers in Beverly Hills, CA | 39 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 66 payments worth $50,550 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $37,884 |
|---|---|
| GlaxoSmithKline, LLC. | $4,225 |
| AstraZeneca UK Limited | $3,783 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,988 |
| Merck Kgaa | $1,880 |
| AbbVie Inc. | $367 |
| UCB, Inc. | $273 |
| Amgen Inc. | $94.45 |
| Compensation for services other than consulting (speaking, faculty) | $29,970 |
|---|---|
| Travel and Lodging | $12,103 |
| Consulting Fee | $6,948 |
| Food and Beverage | $1,529 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Mar 13, 2025 | Travel and Lodging SAPHNELO · Inflammation and Autoimmunity · travel to New York, NY · in-kind Company’s descriptionSpeaker Expenses | $5,363 |
| AstraZeneca Pharmaceuticals LP Sep 18, 2025 | Travel and Lodging SAPHNELO · Inflammation and Autoimmunity · travel to New York, NY · in-kind Company’s descriptionSpeaker Expenses | $4,590 |
| AstraZeneca Pharmaceuticals LP Jan 3, 2025 | Compensation for services other than consulting (speaking, faculty) SAPHNELO · Inflammation and Autoimmunity Company’s descriptionSpeaker Fee | $4,300 |
| AstraZeneca Pharmaceuticals LP Mar 19, 2025 | Compensation for services other than consulting (speaking, faculty) SAPHNELO · Inflammation and Autoimmunity Company’s descriptionSpeaker Fee | $4,300 |
| AstraZeneca Pharmaceuticals LP Mar 21, 2025 | Compensation for services other than consulting (speaking, faculty) SAPHNELO · Inflammation and Autoimmunity Company’s descriptionSpeaker Fee | $4,300 |
| AstraZeneca Pharmaceuticals LP Sep 22, 2025 | Compensation for services other than consulting (speaking, faculty) SAPHNELO · Inflammation and Autoimmunity Company’s descriptionSpeaker Fee | $4,300 |
| AstraZeneca Pharmaceuticals LP Sep 24, 2025 | Compensation for services other than consulting (speaking, faculty) SAPHNELO · Inflammation and Autoimmunity Company’s descriptionSpeaker Fee | $3,750 |
| AstraZeneca UK Limited Jun 5, 2025 | Consulting Fee SAPHNELO · Inflammation and Autoimmunity Company’s descriptionResearch Related Service | $3,088 |
| AstraZeneca Pharmaceuticals LP Feb 25, 2025 | Compensation for services other than consulting (speaking, faculty) SAPHNELO · Inflammation and Autoimmunity Company’s descriptionSpeaker Fee | $2,500 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Sep 23, 2025 | Consulting Fee | $1,980 |
All 21 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Sep 24, 2025 | Compensation for services other than consulting (speaking, faculty) SAPHNELO · Inflammation and Autoimmunity Company’s descriptionSpeaker Fee | $3,750 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Sep 23, 2025 | Consulting Fee | $1,980 |
| AstraZeneca Pharmaceuticals LP Sep 22, 2025 | Compensation for services other than consulting (speaking, faculty) SAPHNELO · Inflammation and Autoimmunity Company’s descriptionSpeaker Fee | $4,300 |
| AstraZeneca Pharmaceuticals LP Sep 18, 2025 | Travel and Lodging SAPHNELO · Inflammation and Autoimmunity · travel to New York, NY · in-kind Company’s descriptionSpeaker Expenses | $4,590 |
| GlaxoSmithKline, LLC. Aug 21, 2025 | Compensation for services other than consulting (speaking, faculty) BENLYSTA · IMMUNOLOGY | $650 |
| AstraZeneca UK Limited Jun 5, 2025 | Consulting Fee SAPHNELO · Inflammation and Autoimmunity Company’s descriptionResearch Related Service | $3,088 |
| GlaxoSmithKline, LLC. Jun 4, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,300 |
| AstraZeneca UK Limited May 21, 2025 | Compensation for services other than consulting (speaking, faculty) in-kind Company’s descriptionMembership Fee | $695 |
| GlaxoSmithKline, LLC. May 5, 2025 | Compensation for services other than consulting (speaking, faculty) BENLYSTA · IMMUNOLOGY | $1,300 |
| GlaxoSmithKline, LLC. Mar 27, 2025 | Compensation for services other than consulting (speaking, faculty) BENLYSTA · IMMUNOLOGY | $325 |
| AstraZeneca Pharmaceuticals LP Mar 21, 2025 | Compensation for services other than consulting (speaking, faculty) SAPHNELO · Inflammation and Autoimmunity Company’s descriptionSpeaker Fee | $4,300 |
| AstraZeneca Pharmaceuticals LP Mar 19, 2025 | Compensation for services other than consulting (speaking, faculty) SAPHNELO · Inflammation and Autoimmunity Company’s descriptionSpeaker Fee | $4,300 |
| AstraZeneca Pharmaceuticals LP Mar 14, 2025 | Compensation for services other than consulting (speaking, faculty) SAPHNELO · Inflammation and Autoimmunity Company’s descriptionSpeaker Fee | $1,600 |
| AstraZeneca Pharmaceuticals LP Mar 13, 2025 | Travel and Lodging SAPHNELO · Inflammation and Autoimmunity · travel to New York, NY · in-kind Company’s descriptionSpeaker Expenses | $5,363 |
| AstraZeneca Pharmaceuticals LP Mar 13, 2025 | Travel and Lodging SAPHNELO · Inflammation and Autoimmunity · travel to New York, NY · in-kind Company’s descriptionSpeaker Expenses | $1,651 |
| GlaxoSmithKline, LLC. Feb 27, 2025 | Compensation for services other than consulting (speaking, faculty) BENLYSTA · IMMUNOLOGY | $650 |
| AstraZeneca Pharmaceuticals LP Feb 25, 2025 | Compensation for services other than consulting (speaking, faculty) SAPHNELO · Inflammation and Autoimmunity Company’s descriptionSpeaker Fee | $2,500 |
| Merck Kgaa Feb 4, 2025 | Consulting FeeCompany’s descriptionAdvisory Board Participation (Fee For Service) | $1,880 |
| AstraZeneca Pharmaceuticals LP Jan 31, 2025 | Travel and Lodging SAPHNELO · Inflammation and Autoimmunity · travel to Denver, CO · in-kind Company’s descriptionSpeaker Expenses | $266 |
| AstraZeneca Pharmaceuticals LP Jan 31, 2025 | Travel and Lodging SAPHNELO · Inflammation and Autoimmunity · travel to Denver, CO · in-kind Company’s descriptionSpeaker Expenses | $233 |
| AstraZeneca Pharmaceuticals LP Jan 3, 2025 | Compensation for services other than consulting (speaking, faculty) SAPHNELO · Inflammation and Autoimmunity Company’s descriptionSpeaker Fee | $4,300 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 7 companies. The companies reported $389,207 in research payments for these studies, mostly to the institutions running them.
- A Phase 2a, Open Label, Multicenter, Platform Trial to Assess the Safety, Tolerability, and Efficacy of Inebilizumab and Blinatumomab in Subjects With Autoimmune Diseases
Amgen Inc. - A phase 4, multicenter, prospective, open-label study describing the e
GlaxoSmithKline, LLC. - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
AbbVie Inc. · Active, not recruiting · NCT05843643 - A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
UCB SA · Enrolling by invitation · NCT04976322 - M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE)
AbbVie Inc. - Randomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN
Genentech, Inc. - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE)
AbbVie Inc. - LUPKYNIS Registry Study
Aurinia Pharma U.S., Inc. - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity
Amgen Inc. - A Phase 2a, Open label, Multi center, Platform Trial to Assess the Safety, Tolerability, and Efficacy of Inebilizumab and Blinatumomab in Subjects With Select Autoimmune Diseases
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.